GlassScriptPhysician profile
Julie A Catlin
NPI 1902907827
$17,846.32
in general payments reported to CMS, 2019-2025
34 companies · $4,601 in 2025
The $4,601 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,049 · 2022: $3,367 · 2023: $3,703 · 2024: $4,126 · 2025: $4,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,220.15 |
| Education | $210.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,748.76 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $2,396.97 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,470.94 | 2021-2025 | |
| Ucb, INC. | $1,235.44 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $1,044.82 | 2021-2025 | |
| Lilly USA, LLC | $963.47 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $942.84 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $857.53 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $743.50 | 2021-2025 | |
| Amgen INC. | $610.04 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $566.99 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $565.21 | 2023-2024 | Vtama |
| Incyte Corporation | $559.96 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $513.25 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $251.49 | 2024-2025 | Zoryve |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $241.61 | 2021-2025 | Klisyri, Seysara |
| Verrica Pharmaceuticals INC. | $213.95 | 2023-2024 | Ycanth |
| Organon LLC | $157.01 | 2024-2025 | Vtama |
| Galderma Laboratories, L.P. | $152.82 | 2021-2025 | Aklief, Nemluvio, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $103.16 | 2021-2025 | Jublia, Cabtreo, Duobrii |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Strata Skin Sciences, INC. | $51.89 | 2024-2025 | Xtrac |
| Journey Medical Corporation | $49.16 | 2023-2025 | |
| Organogenesis INC. | $49.03 | 2025 | Puraply Wound Matrix |
| Paratek Pharmaceuticals, INC. | $45.04 | 2022-2025 | Nuzyra |
| Epi Health, LLC | $42.43 | 2021 | |
| Mayne Pharma Commercial LLC | $40.32 | 2023 | |
| Sebela Pharmaceuticals INC. | $33.78 | 2021 | |
| Fresenius Kabi USA, LLC | $26.46 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $23.80 | 2022 | |
| Revance Therapeutics, INC. | $20.27 | 2024 | Daxxify |
| Biofrontera INC. | $19.32 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Medimetriks Pharmaceuticals, INC. | $17.57 | 2025 | |
| Kyowa Kirin, INC. | $15.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Catlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.